glp 1 drugs and rheumatoid arthritis GLP-1 Reduce Symptoms Glucagon-like peptide-1 receptor agonists in
Description
Because systemic estrogen affects insulin sensitivity and fat distribution, it can influence the broader metabolic baseline that GLP-1 therapy interacts with
Nevertheless, early observational studies and subgroup analyses suggest that metabolic improvements may still occur regardless of baseline BMI
Poster Presentation
Pharmacokinetic actions of exendin-4 in the rat:comparison with glucagon-like peptide-1
Meanwhile, abrupt discontinuation of GLP-1 RAs during the perioperative period may worsen glycemic control, increase insulin requirements, and negate established cardiometabolic and renal benefits, potentially introducing additional perioperative risk [7]
